TD Cowen cuts ICON stock price target to $254, maintains Buy rating
TD Cowen adjusted its financial outlook for ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries.
Investing25d
TD Cowen maintains ICON stock Buy rating on revenue guidance
Tuesday, TD Cowen reaffirmed its Buy rating and $285.00 price target on ICON plc shares (NASDAQ:ICLR), following the company's financial guidance. According to InvestingPro analysis, ICON ...
Morningstar26d
Financial Scenario Analysis With Examples
Financial scenario analysis and stress testing sidestep some of the jeremiads against forecasting by clearly stating the conditions of the model. The “what if” in scenario analysis is ...
Morningstar25d
ICON Issues Financial Guidance for Full Year 2025
ICON plc, (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2025.